GeneDx (NASDAQ:WGS) Releases Earnings Results, Beats Expectations By $0.20 EPS

GeneDx (NASDAQ:WGS) released its quarterly earnings data on Monday. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.20, FiscalAI reports. The firm had revenue of $114.44 million during the quarter, compared to the consensus estimate of $111.01 million. GeneDx had a positive return on equity of 3.97% and a negative net margin of 23.41%.During the same period last year, the business posted $0.36 EPS.

Here are the key takeaways from GeneDx’s conference call:

• Record testing volume and return to profitability: GeneDx processed 30,785 exome and genome tests in Q2, up 32% year over year, generated $114.4 million in revenue, and posted $0.4 million in adjusted net income. The company reaffirmed full-year revenue guidance of $475 million–$490 million and expects to remain profitable for 2026.
• Coverage expansion creates a potential reimbursement tailwind: Commercial genome coverage increased from 47% to 87% of covered lives, driven largely by Carelon, while 39 states now cover exome or genome testing through Medicaid. Management expects the revenue impact to begin emerging in Q4 2026 and become more significant in 2027 as coverage translates into claims payments.
• Revenue cycle management is the primary growth opportunity but remains early: The outpatient genome collection rate was approximately 32%, with exome rates described as comparable, versus management’s long-term target of roughly 70%. Payer-specific workflows, improved prior authorization and denial management, and technology investments are being implemented, but collection rates are expected to remain roughly flat in Q3.
• Demand is broadening beyond GeneDx’s core markets: The company maintained about 80% share among geneticists and reached roughly 50% among pediatric neurologists, while General Pediatrics and prenatal testing showed early growth. New sales representatives, corporate pediatric accounts, and the planned “one-minute” ordering tool are expected to support further adoption.
• Liquidity and operating efficiency improved: GeneDx completed its planned $25 million in annual cost reductions, expanded its debt facility by $50 million, and received a strategic equity investment from Blackstone Life Sciences, bringing pro forma liquidity to approximately $188 million. Management also cited gross-margin improvement to 70%, additional AI-driven productivity opportunities, and a return to cash-flow generation expected in Q4.

GeneDx Stock Up 4.5%

WGS stock opened at $70.90 on Wednesday. GeneDx has a one year low of $32.21 and a one year high of $170.87. The stock has a market capitalization of $2.11 billion, a P/E ratio of -26.46 and a beta of 1.92. The company has a 50 day moving average price of $61.51 and a two-hundred day moving average price of $69.06. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09.

Analyst Upgrades and Downgrades

WGS has been the subject of a number of research analyst reports. Wall Street Zen cut GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings cut shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. BTIG Research restated a “buy” rating and set a $90.00 target price on shares of GeneDx in a report on Tuesday. Craig Hallum reissued a “buy” rating and set a $85.00 price objective on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $89.57.

Insiders Place Their Bets

In related news, CEO Katherine Stueland sold 10,501 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total value of $638,145.77. Following the completion of the transaction, the chief executive officer directly owned 104,372 shares in the company, valued at approximately $6,342,686.44. This represents a 9.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,729 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total value of $226,611.33. Following the transaction, the chief financial officer owned 39,954 shares in the company, valued at $2,428,004.58. This trade represents a 8.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders acquired 2,256,420 shares of company stock worth $93,144,340 and sold 19,135 shares worth $1,128,499. Company insiders own 25.17% of the company’s stock.

Institutional Investors Weigh In On GeneDx

A number of institutional investors have recently bought and sold shares of WGS. Franklin Resources Inc. raised its stake in GeneDx by 101.9% during the third quarter. Franklin Resources Inc. now owns 681,381 shares of the company’s stock worth $73,412,000 after purchasing an additional 343,954 shares during the period. Invesco Ltd. raised its position in shares of GeneDx by 59.2% in the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after buying an additional 292,394 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in GeneDx by 717.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 258,745 shares of the company’s stock valued at $33,652,000 after acquiring an additional 227,088 shares during the last quarter. ARK Investment Management LLC grew its position in GeneDx by 35.3% during the fourth quarter. ARK Investment Management LLC now owns 604,561 shares of the company’s stock valued at $78,629,000 after acquiring an additional 157,582 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in GeneDx by 76.2% during the second quarter. Ameriprise Financial Inc. now owns 255,931 shares of the company’s stock worth $23,625,000 after acquiring an additional 110,684 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.